Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis

Fig. 2

Cumulative probability of change from baseline to week 104 in mSASSS total score. Groups are presented as randomized (patients who switched to standard of care or from placebo to active treatment are analyzed according to the original treatment assignment at randomization). Green, yellow, and red lines represent the change from baseline in total mSASSS score of 0.76 (SDC), 2, and 5, respectively. SDC, smallest detectable change; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us